ImmunoPrecise Antibodies Ltd. (HYFT) — Cash Flow-to-Debt Ratio
ImmunoPrecise Antibodies Ltd. (HYFT) has a Cash Flow-to-Debt Ratio of -0.34x as of October 2025, meaning its operating cash flow of $-2.87 Million could theoretically repay 0% of its total liabilities ($8.40 Million) in one year. See free cash flow generation of ImmunoPrecise Antibodies Ltd. to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ImmunoPrecise Antibodies Ltd. Cash Flow-to-Debt Ratio (1997–2025)
Historical debt coverage capacity for ImmunoPrecise Antibodies Ltd. across 29 annual periods. Also explore HYFT net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for ImmunoPrecise Antibodies Ltd. (1997–2025)
Year-by-year debt coverage analysis for ImmunoPrecise Antibodies Ltd.. For market capitalisation and broader financial context, see how much is ImmunoPrecise Antibodies Ltd. worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.31x | $-6.41 Million | $20.82 Million | ▼ -89.1% |
| 2024 | -0.16x | $-4.25 Million | $26.07 Million | ▲ +83.6% |
| 2023 | -0.99x | $-19.83 Million | $20.01 Million | ▼ -83.4% |
| 2022 | -0.54x | $-9.92 Million | $18.36 Million | ▼ -803.7% |
| 2021 | -0.06x | $-600.00K | $10.04 Million | ▲ +47.7% |
| 2020 | -0.11x | $-1.39 Million | $12.18 Million | ▲ +63.4% |
| 2019 | -0.31x | $-3.21 Million | $10.28 Million | ▼ -8.4% |
| 2018 | -0.29x | $-3.42 Million | $11.87 Million | ▲ +66.6% |
| 2017 | -0.86x | $-721.65K | $836.91K | ▼ -243.3% |
| 2016 | 0.60x | $284.09K | $472.15K | ▲ +524.3% |
| 2015 | -0.14x | $-36.11K | $254.64K | ▲ +7.7% |
| 2014 | -0.15x | $-46.60K | $303.50K | ▼ -840.9% |
| 2013 | -0.02x | $-4.33K | $265.63K | ▲ +97.4% |
| 2012 | -0.62x | $-132.72K | $213.10K | ▲ +34.0% |
| 2011 | -0.94x | $-80.39K | $85.19K | ▲ +69.3% |
| 2010 | -3.07x | $-308.49K | $100.47K | ▼ -197.5% |
| 2009 | -1.03x | $-155.68K | $150.84K | ▲ +92.6% |
| 2008 | -13.97x | $-523.45K | $37.46K | ▼ -632.5% |
| 2007 | -1.91x | $-297.31K | $155.85K | ▼ -139.1% |
| 2006 | -0.80x | $-110.59K | $138.62K | ▲ +54.2% |
| 2005 | -1.74x | $-82.20K | $47.18K | ▲ +51.3% |
| 2004 | -3.58x | $-178.69K | $49.92K | ▲ +65.9% |
| 2003 | -10.51x | $-168.38K | $16.02K | ▼ -604.0% |
| 2002 | -1.49x | $-280.23K | $187.72K | ▼ -16357.5% |
| 2001 | -0.01x | $-8.13K | $896.75K | ▲ +100.0% |
| 2000 | -20.63x | $-208.54K | $10.11K | ▼ -263.7% |
| 1999 | -5.67x | $-202.94K | $35.78K | ▼ -68.5% |
| 1998 | -3.37x | $-226.81K | $67.39K | ▼ -677.8% |
| 1997 | -0.43x | $-108.20K | $250.04K | — |